Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences international limited - cidofovir - cytomegalovirus retinite - antivirali għal użu sistemiku - vistide huwa indikat għall-kura ta 'retinite b'cytomegalovirus f'pazjenti b'sindromu ta' immunodefiċjenza miksuba (aids) u mingħajr disfunzjoni tal-kliewi. vistide għandu jintuża biss meta aġenti oħra huma kkunsidrati bħala mhux adattati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

csl behring gmbh - - bniedem fattur viii tal-koagulazzjoni tal-bniedem, il-fattur von willebrand - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - mard ta 'von willebrand (vwd)profilassi u t-trattament ta' l-emorraġija jew kirurġiku ta ' fsada f'pazjenti b'vwd, meta desmopressin (ddavp) il-kura waħdu huwa ineffettivi jew l-kontra-indikat. l-emofilja a (nuqqas konġenitali tal-fattur viii defiċjenza)profilassi u t-trattament ta ' fsada f'pazjenti b'emofilja a.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - brimica genuair huwa indikat bħala l-manutenzjoni bronkodilatur trattament għall-arja ostruzzjoni u l-serħan mis-sintomi fil-pazjenti adulti bil-marda pulmonari ostruttiva kronika (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide, formoterol fumarate dihydrate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - duaklir genuair huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - agalsidase beta - marda ta 'fabry - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - fabrazyme huwa indikat għal terapija ta 'sostituzzjoni ta' enzimi fit-tul f'pazjenti b'dijanjosi kkonfermata ta 'marda ta' fabry (defiċjenza ta 'α-galaktosidase-a).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drogi użati fid-dijabete - dijabete mellitus fejn huwa meħtieġ it-trattament bl-insulina. insuman rapid huwa wkoll adattat għall-kura ta 'koma ipergliċemika u ketoaċidożi, kif ukoll għall-kisba ta' stabilizzazzjoni minn qabel, intra u wara l-operazzjoni f'pazjenti bid-dijabete mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosoppressanti - jekk jogħġbok irreferi għas-sezzjoni 4. 1 tas-sommarju tal-karatteristiċi tal-prodott fid-dokument ta 'informazzjoni tal-prodott.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.   - decitabine - lewkimja, myeloid - aġenti antineoplastiċi - trattament tal-pazjenti adulti ma intomx ġodda de novo jew sekondarja akuta myeloid lewċemja (aml), skond il-klassifika ta ' l-organizzazzjoni dinjija tas-saħħa (who), li ma jkunux dawk il-kandidati għall-induzzjoni standard chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - emoglobinurja, paroxysmal - immunosuppressanti selettivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.